FDA Approves Sanofi’s Teplizumab for Stage 3 Type 1 Diabetes in Children
The U.S. Food and Drug Administration (FDA) on Friday approved teplizumab (brand name Tzield), a first-in-class immune-modulating therapy developed by Sanofi, for children aged 8 and older with stage 3 ... Read More